Literature DB >> 9311856

Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.

B Chackerian1, L M Rudensey, J Overbaugh.   

Abstract

During progression to AIDS in simian immunodeficiency virus (SIV) Mne-infected macaques, viral variants are selected that encode sequences with serine and threonine changes in variable region 1 (V1) of the surface component of the viral envelope protein (Env-SU). Because these serine and threonine amino acid changes are characteristic of sites for O-linked and N-linked glycosylation, we examined whether they were targets for modification by carbohydrates. For this purpose, we used several biochemical methods for analyzing the Env-SU protein encoded by chimeras of SIVMneCL8 and envelope sequences cloned from an SIVMneCL8-infected Macaca nemestrina during clinical latency and just after the onset of AIDS. The addition of an N-linked glycan was demonstrated by changes in the electrophoretic mobility of Env-SU, and this was verified by specific glycanase digestions and a detailed analysis of the molecular mass of partially purified Env-SU by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Molecular mass calculations by MALDI-TOF MS also demonstrated an increased mass, from 102.3 to 103.5 kDa, associated with serine and threonine residues predicted to be O-linked glycosylation sites. Together, these data provide the first direct evidence that the carbohydrate profile of Env-SU is distinct in SIV variants that evolve during infection of the host. Moreover, our studies show that these changes in glycosylation in V1 were directly associated with changes in antigenicity. Specifically, serine and threonine changes in V1 allowed the virus to escape neutralization by macaque sera that contained antibodies that could neutralize the parental virus, SIVMneCL8. The escape from antibody recognition appeared to be influenced by either O-linked or N-linked carbohydrate additions in V1. Moreover, when glycine residues were engineered at the positions where serine and threonine changes evolve in V1 of SIVMneCL8, there was no change in antigenicity compared to SIVMneCL8. This suggests that the amino acids in V1 are not part of the linear epitope recognized by neutralizing antibody. More likely, V1-associated carbohydrates mask the major neutralizing epitope of SIV. These experiments indicate that the selection of novel glycosylation sites in the V1 region of envelope during the course of disease is driven by humoral immune responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311856      PMCID: PMC192123          DOI: 10.1128/JVI.71.10.7719-7727.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Neutralization of SIVmac239/17E in lymphocyte cultures involves virus strain-specific linear and conformational epitopes encoded by different regions of the env gene including the "V3" domain.

Authors:  Z Wu; G Qian; Q L Zhen; O Narayan; E B Stephens
Journal:  Virology       Date:  1996-08-01       Impact factor: 3.616

2.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

3.  Isolation of a lentivirus from a macaque with lymphoma: comparison with HTLV-III/LAV and other lentiviruses.

Authors:  R E Benveniste; L O Arthur; C C Tsai; R Sowder; T D Copeland; L E Henderson; S Oroszlan
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

4.  Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.

Authors:  J E Hansen; H Clausen; C Nielsen; L S Teglbjaerg; L L Hansen; C M Nielsen; E Dabelsteen; L Mathiesen; S I Hakomori; J O Nielsen
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120.

Authors:  H Geyer; C Holschbach; G Hunsmann; J Schneider
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

6.  Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.

Authors:  P L Nara; W C Hatch; N M Dunlop; W G Robey; L O Arthur; M A Gonda; P J Fischinger
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

7.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

8.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.

Authors:  S Matsushita; M Robert-Guroff; J Rusche; A Koito; T Hattori; H Hoshino; K Javaherian; K Takatsuki; S Putney
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

9.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

10.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

View more
  114 in total

1.  Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain.

Authors:  K Mori; Y Yasutomi; S Ohgimoto; T Nakasone; S Takamura; T Shioda; Y Nagai
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing.

Authors:  S Surman; T D Lockey; K S Slobod; B Jones; J M Riberdy; S W White; P C Doherty; J L Hurwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

3.  Naturally occurring V1-env region variants mediate simian immunodeficiency virus SIVmac escape from high-titer neutralizing antibodies induced by a protective subunit vaccine.

Authors:  H Petry; K Pekrun; G Hunsmann; E Jurkiewicz; W Lüke
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virus.

Authors:  J Glamann; V M Hirsch
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain.

Authors:  Tahar Babas; Daniel Muñoz; Joseph L Mankowski; Patrick M Tarwater; Janice E Clements; M Christine Zink
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.

Authors:  Indresh K Srivastava; Keating VanDorsten; Lucia Vojtech; Susan W Barnett; Leonidas Stamatatos
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

7.  Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

Authors:  James Lue; Mayla Hsu; David Yang; Preston Marx; Zhiwei Chen; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 8.  Challenges in the search for an HIV vaccine.

Authors:  Angelique A C Lemckert; Jaap Goudsmit; Dan H Barouch
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

9.  Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level.

Authors:  Evelien M Bunnik; Zelda Euler; Matthijs R A Welkers; Brigitte D M Boeser-Nunnink; Marlous L Grijsen; Jan M Prins; Hanneke Schuitemaker
Journal:  Nat Med       Date:  2010-08-29       Impact factor: 53.440

10.  Two-dimensional gel-based approaches for the assessment of N-Linked and O-GlcNAc glycosylation in human and simian immunodeficiency viruses.

Authors:  David R M Graham; Megan J Mitsak; Steven T Elliott; Dawn Chen; Stephen A Whelan; Gerald W Hart; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2008-12       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.